

CERTIFICATE OF MAILING


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Kathleen Bodine  
Type or print name

Signature

Date

May 6, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SHEN ET AL.

APPLICATION NO: 10/788,825

FILED: FEBRUARY 27, 2004

FOR: A NON-CRYOGENIC PROCESS FOR FORMING GLYCOSIDES

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.



23914

PATENT TRADEMARK OFFICE

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, reading "Deanna L. Baxam". The signature is written in black ink and is positioned above a horizontal line.

Deanna L. Baxam  
Attorney for Applicants  
Reg. No. 45,266

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4014

Date:

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.  
 LA0100 (NP)  
 APPLICATION NO.  
 10/788,825  
 APPLICANT  
 SHEN ET AL.  
 FILING DATE  
 FEBRUARY 27, 2004

Group

## U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	U.S. APPLICATION DOCUMENT	DATE OF PUBLICATION	NAME	CLASS	SUBCLASS	FILING DATE
AA	2001/0029294	10/11/01	Nickel et al.			

## U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AB	5,534,328	7/9/96	Ashmead et al.			
AC	5,690,763	11/25/97	Ashmead et al.			
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
AK	EP 1 123 734	8/16/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AL						<input type="checkbox"/>	<input type="checkbox"/>
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AP	Greene, T.W. et al., Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., publ. (1999) (table of contents)
AQ	Manabe, S. et al., "Toward Synthesis of Novel C-glycoprotein from Human RNase; Unexpected Stereochemistry of Epoxide Opening Reaction by Organolithium Reagents in the Presence of Lewis Acid", Chemistry Letters, pp. 919-920 (1998)
AR	Rosenblum, S.B. et al., "Synthesis of the Papulacandin C-Arylglucosyl Spiroketal Nucleus", J. Am. Chem. Soc., Vol. 112, No. 7, pp. 2746-2748 (1990)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
LA0100 (NP)  
APPLICATION NO.  
10/788,825  
APPLICANT  
SHEN ET AL.  
FILING DATE  
FEBRUARY 27, 2004

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	2AA	Sollogoub, M. et al., "First Synthesis of 1-deazacytidine, the C-nucleoside analogue of cytidine", Tetrahedron Letters, Vol. 43, pp. 3121-3123 (2002)
	AB	
	AC	
	AD	
	AE	
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.